Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2717 Target Snapshot

Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A · SINGLE PROTEIN · Homo sapiens

408Compounds
126Assays
4Approved Drugs
386.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9HCR9. Use UniProt Q9HCR9 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9HCR9 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A as ChEMBL target CHEMBL2717, mapped to UniProt Q9HCR9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2717
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9HCR9
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A is the right protein anchor across sources, using UniProt Q9HCR9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
UniProt AccessionQ9HCR9
Component TypeProtein
Sequence Length933 aa

Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, mapped to UniProt Q9HCR9. Sequence length is 933 aa.

Mapped IDQ9HCR9
Review nameDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50358.0
KI28.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5437525 9.15 IC50 0.7 Preclinical
CHEMBL282515 8.85 IC50 1.4 Preclinical
CHEMBL284070 8.7 IC50 2.01 Preclinical
CHEMBL33518 8.62 IC50 2.4 Preclinical
CHEMBL4217054 8.57 IC50 2.7 Preclinical
CHEMBL418594 8.46 IC50 3.5 Preclinical
CHEMBL4292389 8.4 IC50 4.0 Preclinical
CHEMBL33121 8.38 IC50 4.2 Preclinical
CHEMBL285737 8.37 IC50 4.3 Preclinical
CHEMBL286309 8.33 IC50 4.7 Preclinical
Distribution

pChEMBL Value Distribution

39
5.0
52
5.5
36
6.0
37
6.5
27
7.0
9
7.5
11
8.0
5
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

VARDENAFIL
CHEMBL1520
Approved 2003
TADALAFIL
CHEMBL779
Approved 2002
DIPYRIDAMOLE
CHEMBL932
Approved 1961
Assay Landscape

Assay Landscape

126
Total Assays
193
Tested Compounds
3
Assay Types
Binding — 120 assays, 193 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 90 131 5.9
cell-based format 26 61 7.1
assay format 4 1 7.4
ADME — 5 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 0
cell-based format 2 3 6.3
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine